Drug Trial Radar · NCT04424290
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
Last checked: Nov 20, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Jun 12, 2020
Primary completion
Apr 28, 2023
Study completion Apr 28, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study. The laser treatment is called panretinal photocoagulation. The purpose of the study is to find out how well different doses of a medicine called BI 764524 are tolerated. BI 764524 is injected into the eye. The study has 2 parts. In the first part, participants get different doses of BI 764524 only once. Participants are in the first part for about 5 months and visit the study site about 8 times. In the second part, participants are put into different groups by chance. Some participants get BI 764524 injections every 4 weeks. Other participants get sham injections every 4 weeks. A sham injection means that it is not a real injection and contains no medicine. Participants cannot tell whether they get the real injection or a sham injection. For the second part, participants are in the study for about 7 months. During this time, they visit the study site about 7 times. In this study, BI 764524 is given to humans for the first time. The doctors compare how well people tolerate the BI 764524 injections and the sham injections. The doctors also regularly check the general health of the participants.
Conditions
- Diabetic Retinopathy
Interventions
BI 764524Drug
BI 764524
Sham control of BI 764524Drug
Sham control of BI 764524
Primary outcomes
What the sponsor says the trial is designed to measure.
- Single-rising Dose (SRD) Part - The Number of Patients With Dose Limiting Events (DLEs) From Drug Administration Until Day 8Time frame: From drug administration (day 1) till day 8, Up to 7±2 days.
- Multiple Dosing (MD) Part - the Number of Patients With Drug-related Adverse Events (AEs) From Drug Administration Until End of Trial.Time frame: From drug administration (day 1) till End of Trial, up to 23 weeks.
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
Trinity Research
Dothan, Alabama
Retina-Vitreous Associates Medical Group
Beverly Hills, California
Stanford University Medical Center
Palo Alto, California
Florida Retina Institute
Orlando, Florida
Raj K. Maturi, MD PC
Carmel, Indiana
Joslin Diabetes Center
Boston, Massachusetts
Long Island Vitreoretinal Consultants
Great Neck, New York
New York Eye and Ear Infirmary of Mount Sinai
New York, New York
Cleveland Clinic
Cleveland, Ohio
Austin Research Center for Retina, PLLC
Austin, Texas
Retina Consultants of Texas
Bellaire, Texas
Valley Retina Institute, PA
McAllen, Texas
Retina Consultants of Texas
The Woodlands, Texas
Bradford Royal Infirmary
Bradford, United Kingdom
Bristol Eye Hospital
Bristol, United Kingdom
Southend University Hospital
Essex, United Kingdom
Gloucestershire Royal Hospital
Gloucester, United Kingdom
Moorfields Eye Hospital
London, United Kingdom
Sunderland Eye Infirmary
Sunderland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.